"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Shares rose 6.4% to $71.73, putting the stock on pace for its highest close since September, according to Dow Jones Market ...

DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...

Researchers who use Fitabase to capture data from Fitbit and Garmin devices will soon be able to capture a new kind of data: continuous glucose monitoring data from Dexcom products. The ability to ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Dexcom (DXCM – Research Report) on January 8 and set a price target of $161.00. Jeff Johnson has given his Buy rating due to a ...